Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up

Annals of Internal Medicine

Volumn 142, Issue 5, 2005, Pages 333-341

  McMahon, Brian J ^a   Bruden, Dana L ^b   Petersen, Kenneth M ^b   Bulkow, Lisa R ^b   Parkinson, Alan J ^b   Nainan, Omana ^b   Khristova, Marina ^b   Zanis, Carolyn ^b   Peters, Helen ^b   Margolis, Harold S ^b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HEPATITIS ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; DNA DETERMINATION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GENDER; GROUPS BY AGE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFANT; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL MODEL; UNITED STATES; VACCINATION; VIREMIA; VIRUS DETECTION; VIRUS IDENTIFICATION;

EID: 20044369702     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-5-200503010-00008     Document Type: Article

References (38)

1. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181:413-8.
2. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796-800.
3. Lai CL, Wong BC, Yeoh EK, Lim WL, Chang WK, Lin HJ. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology. 1993;18:763-7.
4. Yvonnet B, Coursaget P, Chotard J, Sarr M, NDoye R, Chiron JP, et al. Hepatitis B vaccine in infants from an endemic area: long-term anti-HBsAg persistence and revaccination. J Med Virol. 1987;22:315-21.
5. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet. 1991;337:747-50.
6. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209-14.
7. Xu ZY, Duan SC, Margolis HS, Purcell RH, Ou-Yang PY, Coleman PJ, et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B. J Infect Dis. 1995;171:54-60.
8. Stevens CE, Toy PT, Taylor PE, Lee T, Tip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics. 1992;90:170-3.
9. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis. 1993;17:475-9.
10. McMahon BJ, Schoenberg S, Bulkow L, Wainwright RB, Fitzgerald MA, Parkinson AJ, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol. 1993;138:544-9.
11. Heyward WL, Bender TR, McMahon BJ, Hall DB, Francis DP, Lanier AP, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol. 1985;121:914-23.
12. Wainwright RB, McMahon BJ, Bulkow LR, Hall DB, Fitzgerald MA, Harpster AP, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA. 1989;261:2362-6.
13. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results. Arch Intern Med. 1991;151:1634-6.
14. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis. 1997;175:674-7.
15. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759-68.
16. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods. 1996;61:127-34.
17. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol. 2002;68:319-27.
18. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 1984;12:387-95.
19. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, Inc; 1996.
20. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis. 1998;26:933-7.
21. Goh KT, Tan KL, Kong KH, Oon CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Bull World Health Organ. 1992;70:233-9.
22. Milne A, Hopkirk N, Moyes CD. Hepatitis B vaccination in children: persistence of immunity at 9 years [Letter]. J Med Virol. 1994;44:113-4.
23. Tabor E, Cairns J, Gerety RJ, Bayley AC. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J Med Virol. 1993;40:204-9.
24. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-25.
25. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999;29:954-9.
26. Pasko MT, Beam TR Jr. Persistence of anti-HBsAg among health care personnel immunized with hepatitis B vaccine. Am J Public Health. 1990;80:590-3.
27. Barash C, Conn MI, DiMarino AJ Jr, Marzano J, Allen ML. Serologic hepatitis B immunity in vaccinated health care workers. Arch Intern Med. 1999;159:1481-3.
28. Williams JL, Christensen CJ, McMahon BJ, Bulkow LR, Cagle HH, Mayers JS, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine. 2001;19:4081-5.
29. Hadler SC, Coleman PJ, O'Malley P, Judson FN, Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams & Wilkins; 1991:766-8.
30. McMahon BJ, Parkinson AJ. Clinical significance and management when antibody to hepatitis B cote antigen is the sole marker for HBV infection. Viral Hepatitis Review. 2000;6:229-39.
31. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34:194-203.
32. Yotsuyanagi H, Yasuda K, Iino S, Moriya K, Shintani Y, Fujie H, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology. 1998;27:1377-82.
33. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytoroxic T-lymphocyte response. Nat Med. 1996;2:1104-8.
34. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology. 1997;26:786-91.
35. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325-9. [PMID: 1697396]
36. Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, Mendy M, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis. 1994;169:1374-6.
37. Hino K, Katoh Y, Vardas E, Schoub B, Carman WF, Okita K. The effect of introduction of universal childhood vaccination on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants in a developing country [Abstract]. Hepatology. 1999;30:300A.
38. Ogata N, Cote PJ, Zanetti AR, Miller RH, Shapiro M, Gerin J, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology. 1999; 30:779-86.